OncoMatch/Clinical Trials/NCT05608200
Lenvatinib+Sintilimab+TACE vs. Lenvatinib+TACE for Advanced HCC
Is NCT05608200 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Lenvatinib, sintilimab plus TACE and Lenvatinib plus TACE for hepatocellular carcinoma non-resectable.
Treatment: Lenvatinib, sintilimab plus TACE · Lenvatinib plus TACE — This study is conducted to evaluate the efficacy and safety of lenvatinib, sintilimab plus TACE (Len-Sin-TACE) compared with lenvatinib plus TACE (Len-TACE) for patients with advanced hepatocellular carcinoma (HCC).
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Disease stage
Required: Stage BCLC STAGE C, CNLC IIIA, CNLC IIIB
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
Patients who received prior systemic therapy ... for HCC
Cannot have received: immunotherapy
Patients who received prior ... immunotherapy ... for HCC
Cannot have received: TACE
Patients who received prior ... TACE ... for HCC
Cannot have received: transcatheter arterial radioembolization
Patients who received prior ... transcatheter arterial radioembolization (TARE) ... for HCC
Cannot have received: transcatheter arterial embolization
Patients who received prior ... transcatheter arterial embolization (TAE) ... for HCC
Cannot have received: hepatic arterial infusion chemotherapy
Patients who received prior ... hepatic arterial infusion chemotherapy (HAIC) ... for HCC
Cannot have received: radiation therapy
Patients who received prior ... radiation therapy for HCC
Lab requirements
Blood counts
white blood cell count <3.0×10^9/L, platelets <50×10^9/L, prothrombin time prolongation ≥ 4s
Liver function
Child-Pugh class A/B
Child-Pugh class A/B; hematologic examination: white blood cell count <3.0×10^9/L, platelets <50×10^9/L; Prothrombin time prolongation ≥ 4s
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify